A Chinese biotech firm has completed early human testing of an injectable vaccine that trains the immune system to suppress high blood pressure, with one shot possibly lasting months. It is among the world's most advanced hypertension vaccine candidates.
Tianjin-based Oushangyuan has updated its listing prospectus for Shenzhen's ChiNext board, riding China's synthetic biology boom with clients including pharma giant Zhejiang NHU and food conglomerate COFCO. Its receivables have grown fast, drawing scrutiny.
The Shanghai Stock Exchange and China Securities Index Co. will debut two new indexes on September 29, covering innovative drugmakers and software services. The move gives investors fresh tools to track China's fast-growing biotech and software sectors.
Chinese biotech firm BaiRuiJi sees explosive 477% surge on first trading day after Beijing Stock Exchange listing, showcasing investor enthusiasm for healthcare innovation.
You've reached the end
